Can it be compounded in the US?
US pharmacies may compound a drug from a bulk ingredient only if it's an FDA-approved drug ingredient, has a USP monograph, is on FDA's 503A bulks list, or is in Category 1 while FDA evaluates it. No research peptide has been added to the bulks list yet. FDA's advisory committee recommended six in July 2026 (BPC-157, Epithalon, KPV, MOTS-c, Semax, TB-500), but they stay off-limits until FDA finishes rulemaking. Status checked 2026-10-08.
What happened
- Sep 29, 2023FDA places 19 peptides (BPC-157, TB-500, thymosin alpha-1, ipamorelin, CJC-1295, GHK-Cu and others) in 503A Category 2, its significant-safety-risk list.
- Feb 27, 2026HHS Secretary Robert F. Kennedy Jr. says about 14 of the 19 will become compoundable again. An announcement doesn't change FDA's lists by itself.
- Apr 15-22, 2026FDA removes most of the peptides from Category 2 because their nominations were withdrawn, and schedules advisory-committee meetings. Removal doesn't put them on an allowed list.
- Jul 23-24, 2026FDA's Pharmacy Compounding Advisory Committee votes to recommend BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon for the 503A bulks list, against FDA staff's advice, and rejects DSIP (emideltide).
- By Feb 2027Planned advisory-committee review of GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF.
- PendingFDA must decide whether to accept the recommendations, then publish a proposed rule, take comments and issue a final rule. Until then none of these peptides can legally be compounded from bulk. No proposed rule had been published when this page was checked.
Recommended for compounding by FDA's advisory committee, not legal yet
FDA's Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to recommend adding it to the 503A bulks list (FDA staff had recommended against). The vote isn't binding: compounding stays illegal until FDA accepts it and finishes proposed and final rulemaking, which typically takes a year or more. Vote: 8 yes, 6 no, 1 abstain (evaluated for ulcerative colitis).
FDA's Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to recommend adding it to the 503A bulks list (FDA staff had recommended against). The vote isn't binding: compounding stays illegal until FDA accepts it and finishes proposed and final rulemaking, which typically takes a year or more. Vote: 7-5 (evaluated for insomnia).
FDA's Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to recommend adding it to the 503A bulks list (FDA staff had recommended against). The vote isn't binding: compounding stays illegal until FDA accepts it and finishes proposed and final rulemaking, which typically takes a year or more. Vote: 8-6 (evaluated for wound healing and inflammatory conditions).
FDA's Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to recommend adding it to the 503A bulks list (FDA staff had recommended against). The vote isn't binding: compounding stays illegal until FDA accepts it and finishes proposed and final rulemaking, which typically takes a year or more. Vote: 7-5 (evaluated for obesity and osteoporosis).
FDA's Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to recommend adding it to the 503A bulks list (FDA staff had recommended against). The vote isn't binding: compounding stays illegal until FDA accepts it and finishes proposed and final rulemaking, which typically takes a year or more. Vote: 8-5 (evaluated for cerebral ischemia, migraine, trigeminal neuralgia).
FDA's Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to recommend adding it to the 503A bulks list (FDA staff had recommended against). The vote isn't binding: compounding stays illegal until FDA accepts it and finishes proposed and final rulemaking, which typically takes a year or more. Vote: 8-6 (evaluated for wound healing).
Under review: advisory committee meeting planned by February 2027
Non-injectable GHK-Cu (topical etc.) is back in Category 1, so pharmacies may compound it while FDA evaluates. Injectable GHK-Cu was removed from Category 2 in April 2026 and isn't on any allowed list. FDA plans advisory-committee review before the end of February 2027.
Removed from Category 2 in April 2026; FDA plans to put it to its compounding advisory committee before the end of February 2027. Until FDA adds it to the 503A bulks list, US pharmacies can't compound it from bulk.
Compounding allowed while FDA evaluates (Category 1)
In 503A Category 1: pharmacies may compound it while FDA evaluates it.
NAD and NADH are in 503A Category 1: pharmacies may compound them while FDA evaluates them.
Vasoactive intestinal peptide is in 503A Category 1: pharmacies may compound it while FDA evaluates it.
FDA-approved drugs
FDA-approved (Tymlos) for osteoporosis.
FDA-approved (Caverject, Edex, Muse); also a common ingredient in compounded erectile-dysfunction injections.
FDA-approved (Trulicity). It's a biologic-sized fusion protein; compounded versions aren't a recognised option.
FDA-approved as levocarnitine (Carnitor).
FDA-approved (Victoza, Saxenda), with generics available.
Approved as afamelanotide (Scenesse implant) for erythropoietic protoporphyria; injectable research melanotan-I isn't an approved product.
FDA-approved (Pitocin) for labor; compounded nasal oxytocin is made from the approved ingredient.
FDA-approved as bremelanotide (Vyleesi) for low sexual desire in premenopausal women.
FDA-approved (Symlin) for diabetes.
FDA-approved (Ozempic, Wegovy, Rybelsus). The shortage ended in 2025, so pharmacies can no longer make copies of it; compounding is limited to genuine patient-specific changes. Research-chemical semaglutide isn't a legal drug.
FDA-approved (Imcivree) for specific genetic obesity syndromes.
FDA-approved (Forteo and others) for osteoporosis.
FDA-approved (Egrifta) for HIV-associated abdominal fat.
FDA-approved (Mounjaro, Zepbound). The shortage ended in December 2024, so pharmacies can no longer make copies of it; compounding is limited to genuine patient-specific changes.
FDA-approved (Trelstar, Triptodur).
Cyanocobalamin injection is FDA-approved; methylcobalamin is in 503A Category 1.
Approved biologics (can't be compounded)
FDA-approved biologics (Botox and others); they can't be compounded.
Epoetin is an FDA-approved biologic; biologics can't be compounded from bulk under section 503A.
Chorionic gonadotropin became a regulated biologic in 2020; biologics can't be compounded from bulk under section 503A.
Somatropin is an FDA-approved biologic; biologics can't be compounded from bulk under section 503A.
Menotropins are an FDA-approved biologic; biologics can't be compounded from bulk under section 503A.
Insulins are FDA-approved biologics; biologics can't be compounded from bulk under section 503A.
FDA-approved long-acting growth hormone biologic (Ngenla); can't be compounded.
Off the safety list but on no allowed list (not compoundable)
Removed from FDA's Category 2 on about April 22, 2026 after its nominations were withdrawn. That doesn't add it to any allowed list, so US pharmacies still can't compound it from bulk ingredient. It also remains on FDA's Category 2 safety list for 503B outsourcing facilities.
Removed from FDA's Category 2 on about April 22, 2026 after its nominations were withdrawn. That doesn't add it to any allowed list, so US pharmacies still can't compound it from bulk ingredient.
Advisory committee voted against
Emideltide (DSIP) was the one peptide the advisory committee voted against adding in July 2026. It's off Category 2 but on no allowed list, so it can't be compounded.
On FDA's safety-risk list (Category 2)
On FDA's Category 2 list for 503A and 503B (potential heart-failure signal): it can't be compounded.
Still on FDA's 503A Category 2 list (added September 29, 2023) for potential immunogenicity and limited safety data: it can't be compounded.
Nominated without adequate support (Category 3)
503A Category 3 (nominated without adequate support) and on the 503B Category 2 safety list for injectable and nasal use: not compoundable from bulk.
503A Category 3 (nominated without adequate support) and on the 503B Category 2 safety list: not compoundable from bulk.
Never nominated and not approved (not compoundable)
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it.
Questions people ask
Can BPC-157 be compounded legally in the US?
Not yet. FDA's advisory committee recommended adding BPC-157 to the 503A bulks list in July 2026 (8-6-1), but the vote isn't binding. Pharmacies can only compound it after FDA finishes proposed and final rulemaking.
Which peptides can US pharmacies compound right now?
Among the popular peptides, only those in Category 1 (Glutathione, NAD, VIP, and non-injectable GHK-Cu) and FDA-approved drug ingredients, within FDA's limits on copying approved drugs.
Did RFK Jr. make peptides legal to compound?
No. His February 2026 announcement led FDA to take most peptides off its Category 2 safety list in April 2026, and the advisory committee voted for six of them (BPC-157, Epithalon, KPV, MOTS-c, Semax, TB-500) in July 2026. None can legally be compounded until FDA completes rulemaking.
Does compounding status affect research peptide vendors?
No. Compounding rules cover licensed pharmacies making medicines for patients. Vendors that sell peptides "for research use only" are outside that system; their products aren't compounded or FDA-approved drugs.
Sources: FDA: 503A categories (updated May 14, 2026) · FDA: safety risks of certain bulk drug substances (Apr 22, 2026) · Federal Register: PCAC meeting notice, July 23-24, 2026 · STAT: FDA panel backs compounded BPC-157, KPV (Jul 23, 2026) · AJMC: FDA panel backs 6 peptides for compounding · Orrick: FDA removes 12 peptides from Category 2 (Apr 2026) · FDA: concerns with unapproved GLP-1 drugs · Drugs@FDA. This page explains FDA's compounding lists; it isn't legal advice. Status can change when FDA updates its lists or publishes a rule.